SUBCUTANEOUS TOCILIZUMAB IN ADULTS WITH SYSTEMIC SCLEROSIS: 24 AND 48 WEEK SAFETY AND EFFICACY DATA FROM THE FASSCINATE TRIAL

被引：0
|
作者：
Denton, Christopher [1 ]
Khanna, Dinesh [2 ]
Jahreis, Angelika [3 ]
van Laar, Jacob M. [4 ]
Cheng, Sabrina [3 ]
Spotswood, Helen [5 ]
Pope, Janet E. [6 ]
Allanore, Yannick [7 ]
Mueller-Ladner, Ulf [8 ]
Siegel, Jeffrey [3 ]
Furst, Daniel E. [9 ]
机构：
[1] UCL, Sch Med, Mortimer St, London W1N 8AA, England
[2] Univ Michigan, Div Rheumatol, Ann Arbor, MI 48109 USA
[3] Genentech Inc, Rheumatol, San Francisco, CA 94080 USA
[4] Univ Med Ctr Utrecht, Dept Rheumatol & Clin Immunol, Utrecht, Netherlands
[5] Roche Prod Ltd, Rheumatol, Welwyn Garden City AL7 3AY, Herts, England
[6] St Josephs Hlth Care, Ctr Rheumatol, London, ON, Canada
[7] Paris Descartes Univ, Cochin Inst, Paris, France
[8] Univ Giessen, Kerckhoff Clin, Bad Nauheim, Germany
[9] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA
来源：
RHEUMATOLOGY | 2016年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
O27
引用
收藏
页码：47 / 48
页数：2
相关论文
共 50 条
  • [1] SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN ADULTS WITH SYSTEMIC SCLEROSIS: WEEK 48 DATA FROM THE FASSCINATE TRIAL
    Khanna, D.
    Denton, C. P.
    Jahreis, A.
    van Laar, J. M.
    Cheng, S.
    Spotswood, H.
    Pope, J. E.
    Allanore, Y.
    Mueller-Ladner, U.
    Siegel, J.
    Furst, D. E.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 87 - 88
  • [2] SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN ADULTS WITH SYSTEMIC SCLEROSIS: WEEK 24 DATA FROM A PHASE II/II TRIAL
    Denton, Christopher P.
    Khanna, Dinesh
    van Laar, Jaap M.
    Jahreis, Angelika
    Cheng, Sabrina
    Spotswood, Helen
    Siegel, Jeffrey
    Furst, Daniel E.
    [J]. RHEUMATOLOGY, 2015, 54 : 32 - 32
  • [3] Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis: Week 24 Data from a Phase 2/3 Trial.
    Khanna, Dinesh
    Denton, Christopher P.
    van Laar, Jacob M.
    Jahreis, Angelika
    Cheng, Sabrina
    Spotswood, Helen
    Siegel, Jeffrey
    Furst, Daniel E.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S386 - S386
  • [4] Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial
    Khanna, Dinesh
    Denton, Christopher P.
    Jahreis, Angelika
    van Laar, Jacob M.
    Frech, Tracy M.
    Anderson, Marina E.
    Baron, Murray
    Chung, Lorinda
    Fierlbeck, Gerhard
    Lakshminarayanan, Santhanam
    Allanore, Yannick
    Pope, Janet E.
    Riemekasten, Gabriela
    Steen, Virginia
    Mueller-Ladner, Ulf
    Lafyatis, Robert
    Stifano, Giuseppina
    Spotswood, Helen
    Chen-Harris, Haiyin
    Dziadek, Sebastian
    Morimoto, Alyssa
    Sornasse, Thierry
    Siegel, Jeffrey
    Furst, Daniel E.
    [J]. LANCET, 2016, 387 (10038): : 2630 - 2640
  • [5] SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN EARLY SYSTEMIC SCLEROSIS: RESULTS FROM THE OPEN-LABEL PERIOD OF THE FASSCINATE TRIAL
    Khanna, D.
    Denton, C. P.
    Jahreis, A.
    van Laar, J. M.
    Burke, L.
    Spotswood, H.
    Lin, C. J.
    Pope, J. E.
    Allanore, Y.
    Muller-Ladner, U.
    Siegel, J.
    Furst, D. E.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 531 - 532
  • [6] Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial (vol 387, pg 2630, 2016)
    Khanna, D.
    Denton, C. P.
    Jahreis, Angelika A.
    [J]. LANCET, 2018, 391 (10128): : 1356 - 1356
  • [7] Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)
    Khanna, Dinesh
    Denton, Christopher P.
    Lin, Celia J. F.
    van Laar, Jacob M.
    Frech, Tracy M.
    Anderson, Marina E.
    Baron, Murray
    Chung, Lorinda
    Fierlbeck, Gerhard
    Lakshminarayanan, Santhanam
    Allanore, Yannick
    Pope, Janet E.
    Riemekasten, Gabriela
    Steen, Virginia
    Mueller-Ladner, Ulf
    Spotswood, Helen
    Burke, Laura
    Siegel, Jeffrey
    Jahreis, Angelika
    Furst, Daniel E.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (02) : 212 - 220
  • [8] Safety and Efficacy of Subcutaneous Tocilizumab in Systemic Sclerosis: Results from the Open-Label Period of a Phase 3 Trial
    Khanna, Dinesh
    Lin, Celia J. F.
    Spotswood, Helen
    Siegel, Jeffrey
    Furst, Daniel
    Denton, Christopher
    [J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [9] SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN SYSTEMIC SCLEROSIS: RESULTS FROM THE OPEN-LABEL PERIOD OF THE PHASE 3 FOCUSSCED TRIAL
    Khanna, D.
    Lin, C. J. F.
    Spotswood, H.
    Siegel, J.
    Furst, D.
    Denton, C.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 390 - 390
  • [10] Efficacy and safety of tocilizumab in 48-week treatment in children with systemic juvenile idiopathic arthritis
    Yokota, S.
    Imagawa, T.
    Mori, M.
    Ozawa, R.
    Miyamae, T.
    Ito, S.
    Aihara, Y.
    Nerome, Y.
    Imanaka, H.
    Takei, S.
    Kawano, Y.
    Iwata, N.
    Tomiita, M.
    Miyoshi, M.
    Murata, T.
    Umebayashi, H.
    Nishimoto, N.
    Kishimoto, T.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 110 - 110
12345